JP2022110143A5 - - Google Patents

Download PDF

Info

Publication number
JP2022110143A5
JP2022110143A5 JP2022083947A JP2022083947A JP2022110143A5 JP 2022110143 A5 JP2022110143 A5 JP 2022110143A5 JP 2022083947 A JP2022083947 A JP 2022083947A JP 2022083947 A JP2022083947 A JP 2022083947A JP 2022110143 A5 JP2022110143 A5 JP 2022110143A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
therapeutic agent
dimethylpyridin
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022083947A
Other languages
English (en)
Other versions
JP2022110143A (ja
JP7288999B2 (ja
Filing date
Publication date
Priority claimed from JP2019521248A external-priority patent/JP7079777B2/ja
Application filed filed Critical
Publication of JP2022110143A publication Critical patent/JP2022110143A/ja
Publication of JP2022110143A5 publication Critical patent/JP2022110143A5/ja
Application granted granted Critical
Publication of JP7288999B2 publication Critical patent/JP7288999B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (5)

  1. 式（ＩＩ）で表されるドネペジル
    Figure 2022110143000001
     またはその薬剤学的に許容される塩と併用することを特徴とする、式（Ｉ）で表される（Ｓ）－７－（２－メトキシ－３，５－ジメチルピリジン－４－イル）－１－（テトラヒドロフラン－３－イル）－１Ｈ－ピラゾロ［４，３－ｃ］キノリン－４（５Ｈ）－オン
    Figure 2022110143000002
     またはその薬剤学的に許容される塩を含むアルツハイマー病またはレビー小体型認知症の治療剤。
  2. ドネペジルまたはその薬剤学的に許容される塩が、ドネペジル塩酸塩である請求項１記載の治療剤。
  3. （Ｓ）－７－（２－メトキシ－３，５－ジメチルピリジン－４－イル）－１－（テトラヒドロフラン－３－イル）－１Ｈ－ピラゾロ［４，３－ｃ］キノリン－４（５Ｈ）－オンまたはその薬剤学的に許容される塩が、（Ｓ）－７－（２－メトキシ－３，５－ジメチルピリジン－４－イル）－１－（テトラヒドロフラン－３－イル）－１Ｈ－ピラゾロ［４，３－ｃ］キノリン－４（５Ｈ）－オン マレイン酸塩である請求項１または請求項２記載の治療剤。
  4. アルツハイマー病が、軽度、中等度または高度のアルツハイマー病である請求項１～請求項３のいずれか一項に記載の治療剤。
  5. （Ｓ）－７－（２－メトキシ－３，５－ジメチルピリジン－４－イル）－１－（テトラヒドロフラン－３－イル）－１Ｈ－ピラゾロ［４，３－ｃ］キノリン－４（５Ｈ）－オンまたはその薬剤学的に許容される塩およびドネペジルまたはその薬剤学的に許容される塩が同時にまたは別々に投与される、請求項１～請求項４のいずれか一項に記載の治療剤。
JP2022083947A 2017-06-01 2022-05-23 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤 Active JP7288999B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762513692P 2017-06-01 2017-06-01
US62/513,692 2017-06-01
JP2019521248A JP7079777B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤
PCT/JP2018/020638 WO2018221545A1 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019521248A Division JP7079777B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Publications (3)

Publication Number Publication Date
JP2022110143A JP2022110143A (ja) 2022-07-28
JP2022110143A5 true JP2022110143A5 (ja) 2023-05-18
JP7288999B2 JP7288999B2 (ja) 2023-06-08

Family

ID=64455958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521248A Active JP7079777B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤
JP2022083947A Active JP7288999B2 (ja) 2017-06-01 2022-05-23 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019521248A Active JP7079777B2 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤

Country Status (12)

Country Link
US (1) US11833146B2 (ja)
EP (1) EP3632439B1 (ja)
JP (2) JP7079777B2 (ja)
KR (1) KR102627787B1 (ja)
CN (1) CN110603040B (ja)
AU (1) AU2018276565A1 (ja)
BR (1) BR112019023569A2 (ja)
CA (1) CA3060030A1 (ja)
IL (1) IL270395B (ja)
RU (1) RU2019135834A (ja)
SG (2) SG10202113198TA (ja)
WO (1) WO2018221545A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019023552A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) * 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DE69518075T2 (de) 1994-05-24 2001-03-22 Hoffmann La Roche Tricyclische dicarbonylderivate
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
AU5716898A (en) * 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
MXPA05001434A (es) 2002-08-07 2005-06-06 Mitsubishi Pharma Corp Compuestos de dihidropirazolopiridina.
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
AU2006289838B2 (en) 2005-09-15 2011-08-18 Aska Pharmaceutical Co., Ltd. Heterocyclic compound, and production process and use thereof
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
GEP20125405B (en) 2007-05-11 2012-02-27 Pfizer Amino-heterocyclic compounds
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
PL2404922T3 (pl) 2009-03-05 2017-03-31 Astellas Pharma Inc. Związki chinoksalinowe
MX2011010184A (es) 2009-03-31 2011-10-28 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4 -ona y su uso como moduladores de pde9a.
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
MY170189A (en) 2010-08-12 2019-07-09 Boehringer Ingelheim Int 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
JP5888237B2 (ja) 2010-09-07 2016-03-16 アステラス製薬株式会社 ピラゾロキノリン化合物
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
JP2013051639A (ja) 2011-08-31 2013-03-14 Kyocera Document Solutions Inc 画像形成装置
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
PL2573073T3 (pl) 2011-09-26 2015-04-30 Sanofi Sa Pochodne pirazolochinolinonu, ich wytwarzanie i ich zastosowanie terapeutyczne
RU2605096C2 (ru) 2011-10-07 2016-12-20 ЭЙСАЙ АрЭНДДи МЕНЕДЖМЕНТ КО., ЛТД. Пиразолохинолиновое производное
RU2655171C2 (ru) 2013-04-05 2018-05-24 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Соль производного пиразолохинолина и ее кристалл
BR112019023552A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
CN108563565B (zh) 2018-04-08 2021-12-17 中国人民解放军海军工程大学 飞行着陆引导系统可靠性定量分析模型建立方法

Similar Documents

Publication Publication Date Title
JP2022110143A5 (ja)
IL270395B (en) A therapeutic agent for dementia that combines a pyrozoloquinoline derivative and donepezil
JP2019059760A5 (ja)
ES2236185T3 (es) Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o neuropatico y migrañas.
JP2006523216A5 (ja)
WO2003070236A3 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
JP7177772B2 (ja) ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
JP2005515964A5 (ja)
JP2005537268A5 (ja)
JP2005506370A5 (ja)
JPH09511739A (ja) フィブロミアルギアの処置のためのセロトニンアンタゴニスト（５ｈｔ▲下３▼）の使用
WO2007108010B1 (en) Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
JP2007526285A (ja) Ｐｄｅ５阻害剤のための新規の使用
JP2004506682A5 (ja)
AU764445B2 (en) Use of pyridazino(4,5-(b))indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
JPH11504044A (ja) 治療方法及び医薬製剤
JP2005522432A5 (ja)
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
JP2002535370A5 (ja)
US20230405004A1 (en) Combination therapy of donepezil and tadalafil for the treatment of alzheimer's disease or cognitive impairment
SK22004A3 (sk) Farmaceutická kompozícia na moduláciu cholínergnej funkcie a použitie kombinácie NRPA zlúčeniny a antiemetického/antinauzeózneho činidla na výrobu liečiva
JP2019516791A5 (ja)
US20050250806A1 (en) Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
JP2002535334A5 (ja)
JP2019502734A5 (ja)